Cholesin receptor signalling is active in cardiovascular system-associated adipose tissue and correlates with SGLT2i treatment in patients with diabetes.

On a gene-wise level exposure to SGLT2i treatment was associated with lower expression levels of major regulatory elements of lipid metabolism: PPARG, CEBPA, SREBF2 and cholesin itself (Supplementary Table 6 ) in EAT with an average decrease by 20% of expression and no discernible effect in TAT although the differences did not reach statistical significance due to the limited number of patients in this subgroup analysis.

also in 111,027 other papers